Virpax Pharmaceuticals, Inc. (VRPX) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Virpax Pharmaceuticals, Inc. (VRPX) trades at $0.0002 with AI Score 44/100 (Grade C). Virpax Pharmaceuticals, Inc. is a preclinical-stage pharmaceutical company focused on developing non-opioid pain management and CNS disorder treatments. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for VRPX: VRPX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates VRPX against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
VRPX: 1/3 scored disciplines lean bearish. Dominant signal: Ken Griffin bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Virpax Pharmaceuticals, Inc. (VRPX) Healthcare & Pipeline Overview
Virpax Pharmaceuticals, Inc., a preclinical-stage biotech firm, specializes in innovative drug-delivery systems targeting non-opioid pain management and central nervous system disorders. Their pipeline features novel technologies like topical NSAIDs, injectable liposomal gels, and nanotechnology-based intranasal sprays, positioning them in the evolving pharmaceutical landscape.
What Is the Investment Thesis for VRPX?
Virpax Pharmaceuticals, Inc. presents a high-risk, high-reward investment opportunity characteristic of preclinical-stage biotechnology companies. The company's value hinges on the successful development and commercialization of its drug-delivery technologies. Key value drivers include the progression of Epoladerm, Probudur, and Envelta through clinical trials, with positive data readouts serving as major catalysts. Given the company's small size and limited resources (2 employees), strategic partnerships and collaborations will be crucial for advancing its pipeline. The company's beta of 2.01 indicates high volatility. The lack of revenue and a negative P/E ratio of -0.01 reflect its preclinical status. Successful navigation of regulatory hurdles and demonstration of clinical efficacy are essential for realizing the potential of Virpax's innovative drug delivery systems.
Based on FMP financials and quantitative analysis
VRPX Key Highlights
Virpax Pharmaceuticals is a preclinical-stage company, indicating high potential but also significant risk.
- The company focuses on non-opioid pain management, aligning with current healthcare trends and regulatory pressures to reduce opioid use.
- Virpax's pipeline includes multiple drug-delivery systems, diversifying its risk but also requiring significant capital investment.
- The company's small size (2 employees) suggests a reliance on outsourcing and partnerships for development and commercialization.
- The company has a beta of 2.01, indicating high volatility compared to the broader market.
Who Are VRPX's Competitors?
VRPX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AKTX Akari Therapeutics, Plc | $7.79 | -1.39% | $8.92M | — |
| DRMA Dermata Therapeutics, Inc. | $1.38 | -6.12% | — | |
| PIII P3 Health Partners Inc. | $10.27 | -4.64% | $33.6M | — |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are VRPX's Key Strengths?
Innovative drug-delivery technologies.
- Focus on non-opioid pain management.
- Novel intranasal drug delivery system for targeting the brain.
- Diverse pipeline of preclinical-stage product candidates.
What Are VRPX's Weaknesses?
Preclinical-stage company with no approved products.
- Limited financial resources.
- Small team size (2 employees).
- High reliance on outsourcing and partnerships.
What Could Drive VRPX Stock Higher?
Initiation of Phase 1 clinical trials for Epoladerm in Q4 2026.
- Preclinical data release for AnQlar expected in Q3 2026.
- Seeking strategic partnerships for further development of Probudur.
- Continued research and development of Envelta for CNS disorders.
What Are the Key Risks for VRPX?
Weak fundamentals — a Piotroski F-Score of 0/9 flags soft profitability, leverage or efficiency.
- Failure to secure funding for clinical trials.
- Negative results from clinical trials.
- Regulatory delays or rejection of product candidates.
- Competition from established pharmaceutical companies.
- Dependence on third-party manufacturers and suppliers.
What Are the Growth Opportunities for VRPX?
- Epoladerm for Osteoarthritis: Epoladerm, a topical nonsteroidal anti-inflammatory drug (NSAID) for chronic osteoarthritis of the knee, represents a significant growth opportunity. The osteoarthritis market is substantial, with millions of individuals suffering from the condition. A successful clinical trial and subsequent FDA approval could lead to significant revenue generation. The timeline for commercialization depends on clinical trial progress, but a launch within the next 3-5 years is conceivable, pending positive results and regulatory approval.
- Probudur for Postoperative Pain: Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management, addresses a critical need for effective and non-addictive pain relief. The market for postoperative pain management is large, with millions of surgeries performed annually. Probudur's sustained-release formulation could provide a competitive advantage over existing local anesthetics. Clinical trials are necessary to demonstrate its efficacy and safety, with potential commercialization within 4-6 years if successful.
- Envelta for CNS Disorders: Envelta, a nanotechnology-based intranasal spray for delivering drugs to the brain, offers a novel approach to treating CNS disorders. The ability to bypass the blood-brain barrier could significantly improve drug efficacy and reduce systemic side effects. The market for CNS disorder treatments is substantial and growing. Clinical development and regulatory approval are essential for realizing Envelta's potential, with a possible commercialization timeline of 5-7 years.
- AnQlar for Viral Infections: AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections, including influenza and SARS-CoV-2, presents a timely growth opportunity. The global market for antiviral treatments is substantial, driven by seasonal influenza outbreaks and the ongoing COVID-19 pandemic. Successful development and regulatory approval could lead to significant demand for AnQlar. The timeline for commercialization depends on clinical trial results and regulatory review, but a launch within the next 2-4 years is possible.
- VRP324 for Enhanced Cannabidiol Delivery: VRP324, an investigational formulation for nasal delivery to enhance cannabidiol transport to the brain, taps into the growing market for cannabidiol (CBD)-based therapies. The ability to improve CBD bioavailability and target the brain could offer therapeutic benefits for various neurological conditions. Clinical trials are needed to assess VRP324's efficacy and safety, with potential commercialization within 4-6 years if successful.
What Opportunities Does VRPX Have?
- Partnerships with larger pharmaceutical companies.
- Advancement of product candidates through clinical trials.
- Expansion into new therapeutic areas.
- Licensing agreements for drug-delivery technologies.
What Threats Does VRPX Face?
- Regulatory hurdles and clinical trial failures.
- Competition from established pharmaceutical companies.
- Patent infringement and intellectual property disputes.
- Economic downturn and reduced healthcare spending.
What Are VRPX's Competitive Advantages?
- Proprietary drug-delivery technologies protected by patents.
- Focus on non-opioid pain management, addressing a growing market need.
- Novel intranasal drug delivery system for targeting the brain.
- Pipeline of preclinical-stage product candidates with diverse applications.
What Does VRPX Do?
Founded in 2016 and headquartered in Berwyn, Pennsylvania, Virpax Pharmaceuticals, Inc. is a preclinical-stage pharmaceutical company dedicated to developing innovative drug-delivery systems and drug-releasing technologies. The company's primary focus is on advancing non-opioid and non-addictive pain management treatments, as well as treatments for central nervous system (CNS) disorders. Virpax's approach centers around creating novel formulations and delivery methods to improve drug efficacy, reduce side effects, and enhance patient outcomes. Virpax's pipeline consists of several preclinical-stage product candidates. Epoladerm, a topical nonsteroidal anti-inflammatory drug (NSAID), is being developed for the treatment of chronic osteoarthritis of the knee. Probudur is an injectable local anesthetic liposomal gel technology designed for postoperative pain management, aiming to provide sustained pain relief and reduce the need for opioid analgesics. Envelta, a nanotechnology-based intranasal spray, is designed to deliver metabolically labile peptide drugs directly into the brain, potentially offering a non-invasive treatment option for various CNS conditions. Other product candidates include PES200, another technology for delivering peptide drugs to the brain; AnQlar, an anti-viral barrier intended to prevent or reduce the risk and intensity of viral infections, including influenza and SARS-CoV-2; and VRP324, an investigational formulation for nasal delivery to enhance cannabidiol transport to the brain. These diverse programs reflect Virpax's commitment to addressing unmet medical needs through innovative drug delivery solutions.
What Products and Services Does VRPX Offer?
- Develop drug-delivery systems for non-opioid pain management.
- Create drug-releasing technologies for central nervous system disorders.
- Formulate topical nonsteroidal anti-inflammatory drugs (NSAIDs) for osteoarthritis.
- Design injectable local anesthetic liposomal gels for postoperative pain.
- Utilize nanotechnology-based intranasal sprays for drug delivery to the brain.
- Develop anti-viral barriers to prevent or reduce the risk of viral infections.
- Create nasal formulations to enhance cannabidiol transport to the brain.
How Does VRPX Make Money?
- Develop and patent novel drug-delivery technologies.
- Outsource manufacturing and clinical trials.
- Seek partnerships with larger pharmaceutical companies for commercialization.
- Generate revenue through licensing agreements and royalties.
What Industry Does VRPX Operate In?
The biotechnology industry is characterized by intense competition, high R&D costs, and a lengthy regulatory approval process. Virpax Pharmaceuticals operates within this landscape, focusing on innovative drug-delivery systems to differentiate itself. The market for non-opioid pain management is growing due to concerns about opioid addiction, creating an opportunity for Virpax's Epoladerm and Probudur. Similarly, the market for CNS disorder treatments is expanding, driven by an aging population and increasing prevalence of neurological conditions. Competitors include companies like ACON, AKTX, DRMA, FOXO, and PIII, some of whom are also developing novel drug delivery systems.
Who Are VRPX's Key Customers?
- Pharmaceutical companies seeking innovative drug-delivery technologies.
- Patients suffering from chronic pain and central nervous system disorders.
- Healthcare providers looking for non-opioid pain management solutions.
- Individuals seeking preventative measures against viral infections.
Company Profile
Virpax Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Berwyn, US. The company is led by CEO Jatinder Dhaliwal. VRPX has traded publicly since 2021.
How Virpax Pharmaceuticals, Inc. Is Valued
Relative to its peer group, VRPX's quantitative score of 44/100 is below the peer average of 77/100.
Financial Health
Virpax Pharmaceuticals, Inc.'s Piotroski F-Score is 0/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Forward Outlook
Wall Street analysts project Virpax Pharmaceuticals, Inc. revenue of about $0 for fiscal 2026, with EPS near $-12.50.
VRPX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Virpax has seen increased mentions in social trading circles, suggesting growing awareness. This could translate to higher trading volumes as more eyes focus on the stock.
- Recent insider buying activity, if confirmed, often signals confidence in the company's future prospects. Insiders may believe the stock is undervalued.
- The company's focus on non-opioid pain management solutions aligns with a significant unmet medical need. Success in this area could drive substantial long-term growth.
- Positive community sentiment often reflects optimism about upcoming catalysts, such as clinical trial results or regulatory approvals. This buzz can create positive momentum.
Bear Case
- Sustained negative sentiment in online trading communities can be a leading indicator of potential issues. It's crucial to investigate the root causes of this negativity.
- Increased short selling activity, if present, indicates that a significant number of traders are betting against the stock. This can create downward pressure.
- A lack of news or updates from Virpax can lead to investor uncertainty and speculation. This can be particularly detrimental for smaller biotech companies.
- Even with promising technology, the path to FDA approval is fraught with challenges. Clinical trials can fail, and regulatory hurdles can delay or prevent commercialization.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
VRPX Latest News
No recent news available for VRPX.
VRPX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for VRPX.
Price Targets
Wall Street price target analysis for VRPX.
VRPX MoonshotScore
What does this score mean?
The MoonshotScore rates VRPX 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Jatinder Dhaliwal
CEO
Jatinder Dhaliwal serves as the Chief Executive Officer of Virpax Pharmaceuticals, Inc. His background includes experience in the pharmaceutical and biotechnology industries, with a focus on drug development and commercialization. He has held various leadership positions in companies focused on developing innovative therapies. Dhaliwal's expertise encompasses strategic planning, business development, and financial management. His educational background includes advanced degrees in science and business administration, providing him with a strong foundation for leading a biotechnology company.
Track Record: Under Jatinder Dhaliwal's leadership, Virpax Pharmaceuticals has focused on advancing its pipeline of preclinical-stage product candidates. Key milestones include the development of novel drug-delivery systems and the progression of Epoladerm, Probudur, and Envelta towards clinical trials. Dhaliwal has also focused on securing intellectual property protection for the company's technologies and building strategic partnerships to support its growth.
VRPX OTC Market Information
VRPX trades on the OTC Other market tier of OTC Markets.
- OTC Tier: OTC Other
Common Questions About VRPX (Healthcare)
What does the AI Score mean for VRPX?
VRPX holds an AI Score of 44/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Virpax Pharmaceuticals, Inc. is a preclinical-stage pharmaceutical company focused on developing non-opioid pain management and CNS disorder treatments. Their pipeline includes drug-delivery …
What does Virpax Pharmaceuticals, Inc. do?
Virpax Pharmaceuticals, Inc. is a preclinical-stage pharmaceutical company focused on developing innovative drug-delivery systems and drug-releasing technologies. The company's primary focus is on advancing non-opioid and non-addictive pain management treatments, as well as treatments for central nervous system (CNS) disorders.
What are the main risks for VRPX?
The main risks for Virpax Pharmaceuticals, Inc. include the challenges inherent in developing and commercializing new pharmaceutical products. Clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies pose significant threats. The company's limited financial resources and small team size also increase its vulnerability. Dependence on third-party manufacturers and suppliers adds another layer of risk.
What are the key factors to evaluate for VRPX?
Virpax Pharmaceuticals, Inc. (VRPX) holds an AI score of 44/100 (low). presents a high-risk, high-reward investment opportunity characteristic of preclinical-stage biotechnology companies. Not financial advice.
How frequently does VRPX data refresh on this page?
VRPX's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven VRPX's recent stock price performance?
Virpax Pharmaceuticals, Inc. (VRPX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative drug-delivery technologies. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider VRPX overvalued or undervalued right now?
Virpax Pharmaceuticals, Inc. (VRPX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research VRPX before investing?
Before investing in Virpax Pharmaceuticals, Inc. (VRPX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding VRPX to a portfolio?
Key strength of Virpax Pharmaceuticals, Inc. (VRPX): Innovative drug-delivery technologies. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- AI analysis is pending for VRPX, limiting the depth of financial analysis.
- Preclinical-stage companies are inherently risky investments.